Clinical Trials Logo

Recurrent WHO Grade II Glioma clinical trials

View clinical trials related to Recurrent WHO Grade II Glioma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02208362 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma

Start date: May 18, 2015
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of genetically modified T-cell immunotherapy in treating patients with malignant glioma that has come back (recurrent) or has not responded to therapy (refractory). A T cell is a type of immune cell that can recognize and kill abnormal cells in the body. T cells are taken from the patient's blood and a modified gene is placed into them in the laboratory and this may help them recognize and kill glioma cells. Genetically modified T-cells may also help the body build an immune response against the tumor cells.